u/nl_verzekering

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

NL basisverzekering will not cover it at all, so the mechanism here is "there is no mechanism", which at least has the virtue of clarity.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

Asked the pharmacist to check the wholesaler and had a definite answer in about four minutes.

the shortage listing has an expected resolution date on it

ask for the Beipackzettel or the local equivalent, it answers most questions

Country added to the title.

aussie_pbs_watch is right that the two countries are separate systems and the answers diverge.

pharmacy stock and national supply are different questions

Yes. The starting dose is a tolerance step. It is not supposed to do very much.

Correction: the starting dose is a tolerance step rather than a treatment dose.

nordic_pricing has explained this better than the wiki does, which is saying something.

the reimbursement criteria are published in most member states

pens and vials are the same molecule with different logistics

I would not panic about that. It is on the list of ordinary first-month experiences.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

How to ask a question here so that you get a useful answer.

Say what week you are in, whether you are using a pen or a vial, what country you are in, and what you have already read. Those four facts turn a question that gets three contradictory answers into one that gets a specific one.

And do ask. The basic questions get searched for constantly, so a clear answer here helps a stream of people who will never post. The only genuinely unwelcome thing on this board is being unpleasant to somebody for not knowing something yet.

research-use-only material is not approved for human use, and that belongs in every beginner thread

Pharmacy link removed. No links of any kind here, in any country, for any reason.

ask for the Beipackzettel or the local equivalent, it answers most questions

Left up. It names the member state and the pack size, which is all we ask of a pricing post.

The compounded arrangements changed while I was mid-thread and I was arguing from a superseded position.

reimbursement is national, not European, and that is the whole board

compounded supply arrangements changed and the threads have not caught up

Pharmacy link removed. No links of any kind here, in any country, for any reason.

Nothing on this board is medical advice, and the people answering you — including me — are members with spreadsheets rather than clinicians.

Correcting myself upthread: 16 months between scans, not the figure I gave.

DEXA has a meaningful coefficient of variation, and it differs between machines and protocols. Comparing scans from different clinics adds a systematic offset that is invisible on the report.

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

That comparison is between two different products at two different concentrations, which is where the confusion is coming from.

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

Correcting myself upthread: the criterion I quoted was updated for this year.

Is the prescription from the same country as the pharmacy?

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

week two with nothing happening is normal

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Push back: comparing headline prices across countries without normalising pack size is comparing two different quantities.

What does the local patient information leaflet say?

Where to look instead of asking, which will nearly always be faster.

The national shortage database is public, searchable and carries expected resolution dates. The subsidy criteria for each indication are published. Your pharmacist can check wholesaler availability in a few minutes, which is a different question from what is on the shelf.

Between those three, most questions on this board are answerable in half an hour with primary sources. The board is genuinely useful for experience, pricing comparison and the parts that are not written down anywhere — it is a poor substitute for a document that exists.

Disagree.

tove_ogunleye is right about cross-border recognition being narrower than the summaries suggest.

Cosigning on cross-border prescriptions.

This is the split the whole board depends on. Authorisation is European; payment is national.